461 related articles for article (PubMed ID: 31138506)
21. Frequency, clinical features and differential response to therapy of concurrent
Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D
Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769
[No Abstract] [Full Text] [Related]
22. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.
Salido M; Pijuan L; Martínez-Avilés L; Galván AB; Cañadas I; Rovira A; Zanui M; Martínez A; Longarón R; Sole F; Serrano S; Bellosillo B; Wynes MW; Albanell J; Hirsch FR; Arriola E
J Thorac Oncol; 2011 Jan; 6(1):21-7. PubMed ID: 21107285
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
24. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
[TBL] [Abstract][Full Text] [Related]
25. Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations.
Wang H; Schabath MB; Liu Y; Han Y; Li Q; Gillies RJ; Ye Z
Eur J Radiol; 2016 Nov; 85(11):1934-1940. PubMed ID: 27776643
[TBL] [Abstract][Full Text] [Related]
26. CT features and disease spread patterns in ROS1-rearranged lung adenocarcinomas: comparison with those of EGFR-mutant or ALK-rearranged lung adenocarcinomas.
Woo JH; Kim TJ; Kim TS; Han J
Sci Rep; 2020 Oct; 10(1):16251. PubMed ID: 33005033
[TBL] [Abstract][Full Text] [Related]
27. CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas.
Han X; Fan J; Gu J; Li Y; Yang M; Liu T; Li N; Zeng W; Shi H
Cancer Imaging; 2020 Jul; 20(1):51. PubMed ID: 32690092
[TBL] [Abstract][Full Text] [Related]
28. Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer.
Mori M; Hayashi H; Fukuda M; Honda S; Kitazaki T; Shigematsu K; Matsuyama N; Otsubo M; Nagayasu T; Hashisako M; Tabata K; Uetani M; Ashizawa K
Thorac Cancer; 2019 Apr; 10(4):872-879. PubMed ID: 30811109
[TBL] [Abstract][Full Text] [Related]
29. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma.
Yin K; Feng HB; Li LL; Chen Y; Xie Z; Lv ZY; Guo WB; Lu DX; Yang XN; Yan WQ; Wu YL; Zhang XC
Thorac Cancer; 2020 Feb; 11(2):346-352. PubMed ID: 31794146
[TBL] [Abstract][Full Text] [Related]
30. ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma.
Bi R; Bai Q; Zhu X; Tu X; Cai X; Jiang W; Xu X; Tang S; Ge H; Chang B; Cheng Y; Gan H; Zhou X; Yang W
Diagn Pathol; 2019 Aug; 14(1):96. PubMed ID: 31455365
[TBL] [Abstract][Full Text] [Related]
31. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G
BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.
Ko SJ; Lee YJ; Park JS; Cho YJ; Yoon HI; Chung JH; Kim TJ; Lee KW; Kim K; Jheon S; Kim H; Lee JH; Lee CT
BMC Cancer; 2014 May; 14():312. PubMed ID: 24885886
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations.
Zhou JY; Zheng J; Yu ZF; Xiao WB; Zhao J; Sun K; Wang B; Chen X; Jiang LN; Ding W; Zhou JY
Eur Radiol; 2015 May; 25(5):1257-66. PubMed ID: 25577516
[TBL] [Abstract][Full Text] [Related]
34. Molecular Testing for EGFR Mutations and ALK Rearrangements in the Cytological Specimens From the Patients With Non-Small Cell Lung Cancer.
Wang X; Chen S; Emerson RE; Wu HH; Cramer HM; Curless K; Chang HY; Zhang S; Randolph ML; Cheng L
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):119-124. PubMed ID: 30688675
[TBL] [Abstract][Full Text] [Related]
35. High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.
Xu Y; Chang H; Wu L; Zhang X; Zhang L; Zhang J; Li Y; Shen L; Zhu X; Zhou X; Bai Q
Exp Mol Pathol; 2020 Dec; 117():104548. PubMed ID: 32979347
[TBL] [Abstract][Full Text] [Related]
36. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
[TBL] [Abstract][Full Text] [Related]
37. Rare discrepancies in a driver gene alteration within histologically heterogeneous primary lung cancers.
Zhong WZ; Su J; Xu FP; Zhai HR; Zhang XC; Yang XN; Chen ZY; Chen ZH; Li W; Dong S; Zhou Q; Yang JJ; Liu YH; Wu YL
Lung Cancer; 2015 Nov; 90(2):205-11. PubMed ID: 26391021
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.
Hayashi H; Okamoto I; Kimura H; Sakai K; Nishimura Y; Nishio K; Nakagawa K
Anticancer Res; 2012 Oct; 32(10):4533-7. PubMed ID: 23060582
[TBL] [Abstract][Full Text] [Related]
39. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
Won JK; Keam B; Koh J; Cho HJ; Jeon YK; Kim TM; Lee SH; Lee DS; Kim DW; Chung DH
Ann Oncol; 2015 Feb; 26(2):348-54. PubMed ID: 25403583
[TBL] [Abstract][Full Text] [Related]
40. Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma.
Wang H; Zhang W; Wang K; Li X
Medicine (Baltimore); 2018 Jun; 97(26):e11116. PubMed ID: 29952952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]